Kindred Biosciences, Inc. (KIN)

$ 9.25
+0.01 (+0.11%)
Neutral
Symbol KIN
Price $ 9.25
Beta 1.315
Volume Avg. 1.51M
Market Cap 0.421B
Shares () -
52 Week Range 3.46-9.28
1y Target Est -
DCF Unlevered KIN DCF ->
DCF Levered KIN LDCF ->
ROE -54.55% Strong Sell
ROA -38.53% Strong Sell
Operating Margin -
Debt / Equity 36.48% Neutral
P/E -
P/B 5.25 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest KIN news


Dr. Richard Chin
Healthcare
Drug Manufacturers—Specialty & Generic
Nasdaq Capital Market

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.